CD274 and pneumonitis: The subgroup analysis indicates a higher incidence of any grade pneumonitis in patients treated with PD-1 inhibitors, i.e., pembrolizumab and nivolumab: incidence rate of 5.1% (95% CI [3.8%, 6.8%]) and 4.5% (95% CI [3.8%, 5.5%]), respectively, than PD-L1 inhibitor, i.e., atezolizumab: an event rate of 1.6% (95% CI [0.6%, 4.4%]) (Figure 4).